Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses.
about
Interventions for actinic keratosesNonsurgical innovations in the treatment of nonmelanoma skin cancerCreation of a quality of life instrument for nonmelanoma skin cancer patients.Comprehensive management of actinic keratoses: practical integration of available therapies with a review of a newer treatment approach.Network meta-analysis of the outcome 'participant complete clearance' in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review.Cutaneous field cancerization: clinical, histopathological and therapeutic aspects.Diclofenac in hyaluronic acid gel: an alternative treatment for actinic cheilitis.Actinic keratosis.Management of actinic keratosis: a practical report and treatment algorithm from AKTeam™ expert clinicians.A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in EuropeCost-utility of first-line actinic keratosis treatments in FinlandActinic keratosis: the key event in the evolution from photoaged skin to squamous cell carcinoma. Therapy based on pathogenetic and clinical aspects.Methods and Results Report - Evidence and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis -International League of Dermatological Societies in cooperation with the European Dermatology Forum.Hyaluronic acid in the treatment and prevention of skin diseases: molecular biological, pharmaceutical and clinical aspects.Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin.New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel.Hyaluronan: pharmaceutical characterization and drug delivery.Topical diclofenac in the treatment of actinic keratoses.Solar keratosis: epidemiology, pathogenesis, presentation and treatment.Topical Colchicine Gel versus Diclofenac Sodium Gel for the Treatment of Actinic Keratoses: A Randomized, Double-Blind StudyBowen's disease - a review of newer treatment options.Treating skin cancer with topical cream.Emerging drugs for actinic keratosis.Current and emerging treatment strategies for the treatment of actinic keratosis.Diclofenac gel in the treatment of actinic keratoses.Update on non-melanoma skin cancer and the value of dermoscopy in its diagnosis and treatment monitoring.Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers.Understanding efficacy end-points in studies of field-directed therapy for actinic keratosis.Medical approaches to non-melanoma skin cancer.Lmax and imiquimod 3.75%: the new standard in AK management.The challenges for cancer chemoprevention.Adherence to topical therapies in actinic keratosis: A literature review.Long-term use of a new topical formulation containing piroxicam 0.8% and sunscreen: efficacy and tolerability on actinic keratosis. A proof of concept study.Comparison of the Treatment Guidelines for Actinic Keratosis: A Critical Appraisal and Review.Long-term Follow up of Diclofenac Sodium 3% in 2.5% Hyaluronic Acid Gel for Actinic Keratosis: One-year Evaluation.Measuring the severity of topical 5-fluorouracil toxicity.Reassessment of topical diclofenac/hyaluronan gel for actinic keratoses.Topical diclofenac in hyaluronan gel for the treatment of solar keratoses.Erythema multiforme-like eruption as a result of 'Solaraze' treatment.Allergic contact dermatitis from polyethylene glycol monomethyl ether 350 in Solaraze gel.
P2860
Q24202407-4E04699C-54CA-4B12-B8C6-FD71DC402942Q24632006-5350D688-5259-4683-91BE-056E655AF311Q34231411-DB1E4713-573E-48B5-8539-E716698F18BFQ34299210-5AF1ACCB-BFAC-433F-95AA-D60E566CDDE1Q34336675-D1213AE9-CA62-40AF-BA87-3E1D870BB79BQ34381303-D4F78ACB-BCA9-4E05-A243-0690F37304C8Q34581466-155B49D8-F3ED-49EE-8867-C659E3F6874FQ34681960-95B217D5-89C9-478C-8322-4EFD768322DCQ35115492-A5085289-3B1A-4CC8-A93A-85504E13427CQ35180653-06661796-101D-4E31-BA16-5B7E02148FBFQ35666250-B681066A-10EC-49AD-8D71-528895CC352BQ35672075-F9FABB5B-597F-45D2-8E9A-A8EACAEE94BEQ35767304-99062EBF-B8DB-46A4-9886-2AF1F401D827Q35903490-2F9CF211-3B6B-4471-A2A5-0E1814400121Q36109143-2812A43B-A76A-44CF-9211-114F06799235Q36196699-D2F33925-98CC-4C45-A53F-F983D41ABB60Q36299209-6CE76411-F229-41B2-B5B0-03E201B03B15Q36703886-2629F5F2-3B06-4D55-8AB9-A9A7E9D6F5F6Q36834360-8197407E-A960-43D9-BB3A-B43B98A172CCQ37263792-037F4532-7B15-4F21-935B-6CFE4C2397D4Q37390392-97E9B2B5-0CF0-46D8-AD16-31288A82A745Q37735187-2FF7532F-8ABD-4353-9CAF-D2A3C670C922Q37776509-4B14C449-96C7-4FA3-85CA-88A66D73CC34Q37857684-CF3FA637-3F31-470C-80DD-432067CC67A0Q37900834-8C31CC58-8ABF-4DD0-92F7-5B7A5833BB94Q38101606-1AAF40D3-0EB4-4887-B1AB-589453E271D3Q38106805-B4D36CF0-3451-45DC-8593-AC160F2258EDQ38130333-5C24F3AC-8AE7-41BE-8C33-BCAC963CB572Q38162923-9A29662C-1963-4D24-BCEE-28DD65F29647Q38282402-04D6F350-BCEA-4849-A3A7-AC648BBDFF13Q38643625-1133B25B-4349-41B8-B4CD-2D99CC3DB4A1Q38830180-4A5AACAA-9F1F-47E9-ACC4-CE20BACD92C2Q38885554-3F8BBD51-D414-4ABD-881F-250E2278C120Q39311286-67028AC2-0CD9-4583-A0A2-DCC45512A260Q42155148-E7523B7E-6BA2-496F-A123-3F16BD3C822FQ42461884-0B98A5D9-3FC5-46CC-A13E-9B41C0680893Q44052180-EA7C7869-A93C-43AE-8EDD-D5956C1EE6CFQ44311598-472C2A7D-65DE-496F-9C3E-407753977128Q44604988-EAD65FF5-7394-408B-BBAA-2F28BE5E7EB1Q44695221-A0AAEEFA-CF71-40B1-A7C4-D17F064A2F7C
P2860
Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses.
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses.
@ast
Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses.
@en
Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses.
@nl
type
label
Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses.
@ast
Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses.
@en
Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses.
@nl
prefLabel
Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses.
@ast
Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses.
@en
Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses.
@nl
P2093
P2860
P1476
Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses.
@en
P2093
P2860
P304
P356
10.1046/J.1365-4362.2001.01324.X
P577
2001-11-01T00:00:00Z